Home > Insider Trading > Filing (0000769993-14-000532)

Filing Details

Accession Number:: 0000769993-14-000532
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-08-14 17:26:58
Reporting Period:: 2014-08-12

Filing Date:: 2014-08-14
Accepted Time:: 2014-08-14 17:26:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492674	T2 Biosystems Inc.	TTOO	Surgical & Medical Instruments & Apparatus (3841)	204827488

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
769993	Goldman Sachs & Co	200 West Street New York NY 10282	No	No	No	No
886982	Goldman Sachs Group Inc	200 West Street New York NY 10282	No	No	No	No
1572490	Bridge Street 2013, L.p.	200 West Street New York NY 10282	No	No	No	No
1572491	Bridge Street 2013 Offshore, L.p.	200 West Street New York NY 10282	No	No	No	No
1572501	Mbd 2013, L.p.	200 West Street New York NY 10282	No	No	No	No
1572502	Mbd 2013 Offshore, L.p.	200 West Street New York NY 10282	No	No	No	No
1575993	Broad Street Principal Investments, L.l.c.	200 West Street New York NY 10282	No	No	No	No
1615636	Bridge Street Opportunity Advisors, L.l.c.	200 West Street New York NY 10282	No	No	No	No
1615711	Bridge Street 2013 Holdings, L.p.	200 West Street New York NY 10282	No	No	No	No
1615732	Mbd 2013 Holdings, L.p.	200 West Street New York NY 10282	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-08-12	2,548,150	$0.00	2,548,150	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2014-08-12	909,090	$11.00	3,457,240	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series E Preferred Stock	Disposition	2014-08-12	4,331,858	$0.00	2,548,150	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group"), Goldman, Sachs & Co. ("Goldman Sachs"), MBD 2013, L.P. ("MBD"), MBD 2013 Offshore, L.P. ("MBD Offshore"), MBD 2013 Holdings, L.P. ("MBD Holdings"), Broad Street Principal Investments, L.L.C. ("Broad Street"), Bridge Street 2013, L.P. ("Bridge Street"), Bridge Street 2013 Offshore, L.P. ("Bridge Street Offshore"), and Bridge Street 2013 Holdings, L.P. ("Bridge Street Holdings" and, together with MBD, MBD Offshore, MBD Holdings, Broad Street, Bridge Street, and Bridge Street Offshore, the "GS Funds"), MBD Advisors, L.L.C. ("MBD Advisors") and Bridge Street Opportunity Advisors, L.L.C. ("Bridge Street Advisors" and, together with GS Group, Goldman Sachs, the GS Funds and MBD Advisors, the "Reporting Persons").
Due to the electronic system's limitation of 10 Reporting Persons per joint filing, this statement is being filed in duplicate.
In connection with the closing of the initial public offering (the "IPO") of Common Stock, par value $0.001 per share (the "Common Stock") of T2 Biosystems, Inc. (the "Company"), which occurred on August 12, 2014, 4,331,858 shares of the Company's Series E Preferred Stock (the "Preferred Stock"), beneficially owned directly by certain of the GS Funds, and which may be deemed to have been beneficially owned indirectly by GS Group and Goldman Sachs, automatically converted into 2,548,150 shares of the Company's Common Stock. The Preferred Stock was immediately exercisable and had no expiration date.
In connection with the closing of the IPO on August 12, 2014, 3,638,761 shares of Preferred Stock beneficially owned directly by Broad Street automatically converted into 2,140,447 shares of Common Stock. 537,150 shares of Preferred Stock beneficially owned directly by Bridge Street Holdings, which may be deemed to have been beneficially owned indirectly by each of Bridge Street, Bridge Street Offshore and Bridge Street Advisors by reason of the direct beneficial ownership of Preferred Stock by Bridge Street Holdings, automatically converted into 315,970 shares of Common Stock. 155,947 shares of Preferred Stock beneficially owned directly by MBD Holdings, which may be deemed to have been beneficially owned indirectly by MBD, MBD Offshore and MBD Advisors by reason of the direct beneficial ownership of Preferred Stock by MBD Holdings, automatically converted into 91,733 shares of Common Stock.
On August 12, 2014, in connection with the closing of the IPO, certain of the GS Funds purchased an aggregate of 909,090 shares of Common Stock at the IPO price of $11.00 per share of Common Stock. Broad Street purchased 763,636 shares of Common Stock, Bridge Street Holdings purchased 112,727 shares of Common Stock and MBD Holdings purchased 32,727 shares of Common Stock
GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 3,457,240 shares of Common Stock by reason of the direct beneficial ownership of Common Stock by certain of the GS Funds because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs is a wholly owned subsidiary of GS Group. Goldman Sachs is the investment manager of certain of the GS Funds.
Broad Street beneficially owns directly 2,904,083 shares of Common Stock. Bridge Street Holdings beneficially owns directly 428,697 shares of Common Stock. Bridge Street, Bridge Street Offshore and Bridge Street Advisors may each be deemed to beneficially own indirectly 428,697 shares of Common Stock by reason of the direct beneficial ownership of Common Stock by Bridge Street Holdings. MBD Holdings beneficially owns directly 124,460 shares of Common Stock. MBD, MBD Offshore and MBD Advisors may each be deemed to beneficially own indirectly 124,460 shares of Common Stock by reason of the direct beneficial ownership of Common Stock by MBD Holdings.
Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.